Moleculin Biotech Inc [NASDAQ: MBRX] surged by $0.08 during the normal trading session on Monday and reaching a high of $0.7129 during the day while it closed the day at $0.63.
Moleculin Biotech Inc stock has also gained 62.06% of its value over the past 7 days. However, MBRX stock has declined by -13.81% in the 3 months of the year. Over the past six months meanwhile, it has lost -64.60% and lost -81.41% year-on date.
The market cap for MBRX stock reached $15.19 million, with 24.10 million shares outstanding and 21.99 million shares in the current float. Compared to the average trading volume of 4.31M shares, MBRX reached a trading volume of 9880102 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moleculin Biotech Inc [MBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MBRX shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Moleculin Biotech Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 09, 2025. The new note on the price target was released on February 12, 2025, representing the official price target for Moleculin Biotech Inc stock. Previously, the target price had yet another raise to $14, while Oppenheimer analysts kept a Outperform rating on MBRX stock.
The Price to Book ratio for the last quarter was 212.15, with the Price to Cash per share for the same quarter was set at 0.32.
MBRX stock trade performance evaluation
Moleculin Biotech Inc [MBRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 62.06. With this latest performance, MBRX shares dropped by -8.61% in over the last four-week period, additionally sinking by -64.60% over the last 6 months – not to mention a drop of -62.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MBRX stock in for the last two-week period is set at 57.60, with the RSI for the last a single of trading hit 0.1057, and the three-weeks RSI is set at 0.0949 for Moleculin Biotech Inc [MBRX]. The present Moving Average for the last 50 days of trading for this stock 0.7177, while it was recorded at 0.5615 for the last single week of trading, and 1.5195 for the last 200 days.
Moleculin Biotech Inc [MBRX]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -89.59%, with Return on Assets sitting at -89.59%.
Earnings per share (EPS) analysis for Moleculin Biotech Inc [MBRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moleculin Biotech Inc go to 42.60%.
Moleculin Biotech Inc [MBRX]: Institutional Ownership
There are presently around $6.13%, or 6.42% of MBRX stock, in the hands of institutional investors. The top three institutional holders of MBRX stocks are: ARMISTICE CAPITAL, LLC with ownership of 0.16 million shares, which is approximately 6.1339%. VANGUARD GROUP INC, holding 84418.0 shares of the stock with an approximate value of $$0.3 million in MBRX stocks shares; and VANGUARD GROUP INC, currently with $$0.12 million in MBRX stock with ownership which is approximately 1.3272%.
